Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma
Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Adrian L. Harris(University of Oxford), Richard Harrop(Oxford BioMedica (United Kingdom)), Linda R. White(Norwegian University of Science and Technology), Denis Talbot(Cancer Research UK), Andreas Makris(Institute of Cancer Research), Andrew Slade(Oxford BioMedica (United Kingdom)), Rachel J. Gibson(Royal Adelaide Hospital), S. Kingsman(Oxford BioMedica (United Kingdom)), Miles W. Carroll(Institute of Human Genetics), Martin Förster, Stuart Naylor(Oxford BioMedica (United Kingdom)), Jan Steiner(Oxford BioMedica (United Kingdom)), O. Kan(Oxford BioMedica (United Kingdom)), G. Deplanque, Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 99
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k